Cargando…

Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis

A 71‐year‐old man was diagnosed with squamous cell lung carcinoma with high expression of programmed cell death ligand 1 (PDL1) (cT4N1M1b stage IVA). He was treated with pembrolizumab, but 14 days later, he suffered from pembrolizumab‐related retinal vasculitis as an immune‐related adverse event (ir...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Chihiro, Tachihara, Motoko, Kusuhara, Sentaro, Fukuoka, Hidenori, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938210/
https://www.ncbi.nlm.nih.gov/pubmed/33732464
http://dx.doi.org/10.1002/rcr2.730